Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;24(4):284-293.
doi: 10.1016/j.tim.2015.12.004. Epub 2015 Dec 30.

The Interplay of Dengue Virus Morphological Diversity and Human Antibodies

Affiliations
Review

The Interplay of Dengue Virus Morphological Diversity and Human Antibodies

Shee-Mei Lok. Trends Microbiol. .

Abstract

Dengue virus (DENV) infects ∼400 million people annually, and there is no available vaccine or therapeutics. It is not clear why candidate vaccines provide only modest protection. In addition to the presence of four different dengue serotypes, there is also structural heterogeneity in DENV infectious particles, even within a strain. This severely complicates the development of vaccines and therapeutics. The currently known different morphologies of DENV are: immature, partially mature, compact mature, and expanded mature forms of the virus. In this review I describe these forms of the virus, their infectivity, and how antibodies could recognize these morphologies. I also discuss possible vaccine and antibody therapeutic formulations to protect against all morphologies.

Keywords: antibodies; dengue virus; morphologies; therapeutics; vaccines.

Similar articles

See all similar articles

Cited by 16 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback